nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylprednisolone—ankylosing spondylitis—osteoporosis	0.496	1	CtDrD
Methylprednisolone—Exemestane—Estropipate—osteoporosis	0.136	0.569	CrCrCtD
Methylprednisolone—Exemestane—Conjugated Estrogens—osteoporosis	0.103	0.431	CrCrCtD
Methylprednisolone—ABCB1—Ethinyl Estradiol—osteoporosis	0.0202	0.133	CbGbCtD
Methylprednisolone—CYP3A4—Estropipate—osteoporosis	0.0188	0.124	CbGbCtD
Methylprednisolone—CYP3A4—Calcitriol—osteoporosis	0.0188	0.124	CbGbCtD
Methylprednisolone—CYP3A4—Ergocalciferol—osteoporosis	0.015	0.099	CbGbCtD
Methylprednisolone—ABCB1—Conjugated Estrogens—osteoporosis	0.0148	0.0978	CbGbCtD
Methylprednisolone—ABCB1—Estradiol—osteoporosis	0.013	0.0859	CbGbCtD
Methylprednisolone—CYP3A4—Raloxifene—osteoporosis	0.0125	0.0827	CbGbCtD
Methylprednisolone—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0121	0.0798	CbGbCtD
Methylprednisolone—CYP3A4—Cholecalciferol—osteoporosis	0.00967	0.0638	CbGbCtD
Methylprednisolone—CYP3A4—Conjugated Estrogens—osteoporosis	0.00888	0.0586	CbGbCtD
Methylprednisolone—CYP3A4—Estradiol—osteoporosis	0.0078	0.0514	CbGbCtD
Methylprednisolone—ABCB1—Drug Induction of Bile Acid Pathway—SLC51A—osteoporosis	0.000463	0.114	CbGpPWpGaD
Methylprednisolone—Exemestane—CYP19A1—osteoporosis	0.000372	0.257	CrCbGaD
Methylprednisolone—Testolactone—CYP19A1—osteoporosis	0.000355	0.246	CrCbGaD
Methylprednisolone—CYP3A4—Drug Induction of Bile Acid Pathway—SLC51A—osteoporosis	0.000285	0.07	CbGpPWpGaD
Methylprednisolone—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—RAP1A—osteoporosis	0.000223	0.0547	CbGpPWpGaD
Methylprednisolone—NR3C1—Signaling events mediated by HDAC Class II—TUBA1B—osteoporosis	0.000221	0.0542	CbGpPWpGaD
Methylprednisolone—Medroxyprogesterone Acetate—SHBG—osteoporosis	0.000209	0.145	CrCbGaD
Methylprednisolone—Hydrocortisone—SHBG—osteoporosis	0.000148	0.102	CrCbGaD
Methylprednisolone—Medroxyprogesterone Acetate—ESR1—osteoporosis	0.000141	0.0976	CrCbGaD
Methylprednisolone—Betamethasone—CYP19A1—osteoporosis	0.000139	0.0963	CrCbGaD
Methylprednisolone—ABCB1—HIF-1-alpha transcription factor network—PKM—osteoporosis	9.48e-05	0.0232	CbGpPWpGaD
Methylprednisolone—NR3C1—Transcription factor regulation in adipogenesis—IRS2—osteoporosis	9.17e-05	0.0225	CbGpPWpGaD
Methylprednisolone—NR3C1—Nuclear Receptors—ESR2—osteoporosis	9.12e-05	0.0224	CbGpPWpGaD
Methylprednisolone—NR3C1—Transcription factor regulation in adipogenesis—LEP—osteoporosis	8.97e-05	0.022	CbGpPWpGaD
Methylprednisolone—Dexamethasone—CYP19A1—osteoporosis	8.11e-05	0.056	CrCbGaD
Methylprednisolone—NR3C1—AP-1 transcription factor network—COL1A2—osteoporosis	8.07e-05	0.0198	CbGpPWpGaD
Methylprednisolone—NR3C1—Transcription factor regulation in adipogenesis—IRS1—osteoporosis	8e-05	0.0196	CbGpPWpGaD
Methylprednisolone—Anxiety—Pamidronate—osteoporosis	7.92e-05	0.000735	CcSEcCtD
Methylprednisolone—Ill-defined disorder—Zoledronate—osteoporosis	7.91e-05	0.000734	CcSEcCtD
Methylprednisolone—Abdominal pain—Alendronate—osteoporosis	7.9e-05	0.000733	CcSEcCtD
Methylprednisolone—Shock—Risedronate—osteoporosis	7.89e-05	0.000732	CcSEcCtD
Methylprednisolone—Nervous system disorder—Risedronate—osteoporosis	7.86e-05	0.000729	CcSEcCtD
Methylprednisolone—Discomfort—Pamidronate—osteoporosis	7.85e-05	0.000729	CcSEcCtD
Methylprednisolone—Angioedema—Zoledronate—osteoporosis	7.79e-05	0.000723	CcSEcCtD
Methylprednisolone—NR3C1—Endoderm Differentiation—DKK1—osteoporosis	7.79e-05	0.0191	CbGpPWpGaD
Methylprednisolone—Skin disorder—Risedronate—osteoporosis	7.79e-05	0.000722	CcSEcCtD
Methylprednisolone—Gastrointestinal pain—Calcitriol—osteoporosis	7.79e-05	0.000722	CcSEcCtD
Methylprednisolone—Abdominal pain—Raloxifene—osteoporosis	7.77e-05	0.000721	CcSEcCtD
Methylprednisolone—Urticaria—Ibandronate—osteoporosis	7.73e-05	0.000717	CcSEcCtD
Methylprednisolone—Malaise—Zoledronate—osteoporosis	7.69e-05	0.000713	CcSEcCtD
Methylprednisolone—Abdominal pain—Ibandronate—osteoporosis	7.69e-05	0.000713	CcSEcCtD
Methylprednisolone—Confusional state—Pamidronate—osteoporosis	7.68e-05	0.000713	CcSEcCtD
Methylprednisolone—NR3C1—AP-1 transcription factor network—NFATC1—osteoporosis	7.67e-05	0.0188	CbGpPWpGaD
Methylprednisolone—Vertigo—Zoledronate—osteoporosis	7.66e-05	0.000711	CcSEcCtD
Methylprednisolone—Syncope—Zoledronate—osteoporosis	7.65e-05	0.000709	CcSEcCtD
Methylprednisolone—Anaphylactic shock—Pamidronate—osteoporosis	7.62e-05	0.000707	CcSEcCtD
Methylprednisolone—Haemoglobin—Estradiol—osteoporosis	7.59e-05	0.000704	CcSEcCtD
Methylprednisolone—Infection—Pamidronate—osteoporosis	7.57e-05	0.000702	CcSEcCtD
Methylprednisolone—Rhinitis—Estradiol—osteoporosis	7.57e-05	0.000702	CcSEcCtD
Methylprednisolone—Urticaria—Calcitriol—osteoporosis	7.56e-05	0.000702	CcSEcCtD
Methylprednisolone—Haemorrhage—Estradiol—osteoporosis	7.55e-05	0.0007	CcSEcCtD
Methylprednisolone—Abdominal pain—Calcitriol—osteoporosis	7.53e-05	0.000698	CcSEcCtD
Methylprednisolone—Angioedema—Conjugated Estrogens—osteoporosis	7.5e-05	0.000696	CcSEcCtD
Methylprednisolone—Shock—Pamidronate—osteoporosis	7.5e-05	0.000695	CcSEcCtD
Methylprednisolone—Loss of consciousness—Zoledronate—osteoporosis	7.49e-05	0.000695	CcSEcCtD
Methylprednisolone—Hypersensitivity—Estropipate—osteoporosis	7.47e-05	0.000693	CcSEcCtD
Methylprednisolone—Nervous system disorder—Pamidronate—osteoporosis	7.47e-05	0.000693	CcSEcCtD
Methylprednisolone—Vomiting—Etidronic acid—osteoporosis	7.45e-05	0.000692	CcSEcCtD
Methylprednisolone—Tachycardia—Pamidronate—osteoporosis	7.44e-05	0.00069	CcSEcCtD
Methylprednisolone—Connective tissue disorder—Estradiol—osteoporosis	7.42e-05	0.000688	CcSEcCtD
Methylprednisolone—ABCB1—Drug Induction of Bile Acid Pathway—VDR—osteoporosis	7.4e-05	0.0181	CbGpPWpGaD
Methylprednisolone—Rash—Etidronic acid—osteoporosis	7.39e-05	0.000686	CcSEcCtD
Methylprednisolone—Convulsion—Zoledronate—osteoporosis	7.39e-05	0.000685	CcSEcCtD
Methylprednisolone—Dermatitis—Etidronic acid—osteoporosis	7.38e-05	0.000685	CcSEcCtD
Methylprednisolone—Vertigo—Conjugated Estrogens—osteoporosis	7.38e-05	0.000684	CcSEcCtD
Methylprednisolone—Hyperhidrosis—Pamidronate—osteoporosis	7.37e-05	0.000683	CcSEcCtD
Methylprednisolone—Syncope—Conjugated Estrogens—osteoporosis	7.36e-05	0.000683	CcSEcCtD
Methylprednisolone—Hypertension—Zoledronate—osteoporosis	7.36e-05	0.000683	CcSEcCtD
Methylprednisolone—Hypersensitivity—Alendronate—osteoporosis	7.36e-05	0.000683	CcSEcCtD
Methylprednisolone—Headache—Etidronic acid—osteoporosis	7.34e-05	0.000681	CcSEcCtD
Methylprednisolone—Musculoskeletal discomfort—Risedronate—osteoporosis	7.3e-05	0.000677	CcSEcCtD
Methylprednisolone—Asthenia—Estropipate—osteoporosis	7.28e-05	0.000675	CcSEcCtD
Methylprednisolone—Visual impairment—Estradiol—osteoporosis	7.27e-05	0.000675	CcSEcCtD
Methylprednisolone—Myalgia—Zoledronate—osteoporosis	7.26e-05	0.000674	CcSEcCtD
Methylprednisolone—Arthralgia—Zoledronate—osteoporosis	7.26e-05	0.000674	CcSEcCtD
Methylprednisolone—Insomnia—Risedronate—osteoporosis	7.25e-05	0.000673	CcSEcCtD
Methylprednisolone—NR3C1—Nuclear Receptors—VDR—osteoporosis	7.24e-05	0.0177	CbGpPWpGaD
Methylprednisolone—Anxiety—Zoledronate—osteoporosis	7.23e-05	0.000671	CcSEcCtD
Methylprednisolone—Loss of consciousness—Conjugated Estrogens—osteoporosis	7.22e-05	0.00067	CcSEcCtD
Methylprednisolone—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	7.21e-05	0.000669	CcSEcCtD
Methylprednisolone—NR3C1—Nuclear Receptor transcription pathway—ESR2—osteoporosis	7.21e-05	0.0177	CbGpPWpGaD
Methylprednisolone—Paraesthesia—Risedronate—osteoporosis	7.2e-05	0.000668	CcSEcCtD
Methylprednisolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—COL1A2—osteoporosis	7.18e-05	0.0176	CbGpPWpGaD
Methylprednisolone—Pruritus—Estropipate—osteoporosis	7.18e-05	0.000666	CcSEcCtD
Methylprednisolone—Discomfort—Zoledronate—osteoporosis	7.17e-05	0.000665	CcSEcCtD
Methylprednisolone—Asthenia—Alendronate—osteoporosis	7.17e-05	0.000665	CcSEcCtD
Methylprednisolone—Hypersensitivity—Ibandronate—osteoporosis	7.17e-05	0.000665	CcSEcCtD
Methylprednisolone—Hypotension—Pamidronate—osteoporosis	7.12e-05	0.000661	CcSEcCtD
Methylprednisolone—Convulsion—Conjugated Estrogens—osteoporosis	7.11e-05	0.00066	CcSEcCtD
Methylprednisolone—Fatigue—Ethinyl Estradiol—osteoporosis	7.09e-05	0.000658	CcSEcCtD
Methylprednisolone—Pruritus—Alendronate—osteoporosis	7.07e-05	0.000656	CcSEcCtD
Methylprednisolone—Dyspepsia—Risedronate—osteoporosis	7.06e-05	0.000655	CcSEcCtD
Methylprednisolone—Eye disorder—Estradiol—osteoporosis	7.05e-05	0.000655	CcSEcCtD
Methylprednisolone—Confusional state—Zoledronate—osteoporosis	7.02e-05	0.000651	CcSEcCtD
Methylprednisolone—Hypersensitivity—Calcitriol—osteoporosis	7.01e-05	0.000651	CcSEcCtD
Methylprednisolone—Cardiac disorder—Estradiol—osteoporosis	7.01e-05	0.00065	CcSEcCtD
Methylprednisolone—Arthralgia—Conjugated Estrogens—osteoporosis	6.99e-05	0.000649	CcSEcCtD
Methylprednisolone—Myalgia—Conjugated Estrogens—osteoporosis	6.99e-05	0.000649	CcSEcCtD
Methylprednisolone—Asthenia—Ibandronate—osteoporosis	6.98e-05	0.000647	CcSEcCtD
Methylprednisolone—Anxiety—Conjugated Estrogens—osteoporosis	6.97e-05	0.000646	CcSEcCtD
Methylprednisolone—Nausea—Etidronic acid—osteoporosis	6.96e-05	0.000646	CcSEcCtD
Methylprednisolone—Anaphylactic shock—Zoledronate—osteoporosis	6.96e-05	0.000646	CcSEcCtD
Methylprednisolone—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	6.94e-05	0.000644	CcSEcCtD
Methylprednisolone—Musculoskeletal discomfort—Pamidronate—osteoporosis	6.94e-05	0.000644	CcSEcCtD
Methylprednisolone—Diarrhoea—Estropipate—osteoporosis	6.94e-05	0.000644	CcSEcCtD
Methylprednisolone—Infection—Zoledronate—osteoporosis	6.91e-05	0.000641	CcSEcCtD
Methylprednisolone—Fatigue—Risedronate—osteoporosis	6.91e-05	0.000641	CcSEcCtD
Methylprednisolone—Insomnia—Pamidronate—osteoporosis	6.89e-05	0.000639	CcSEcCtD
Methylprednisolone—Pruritus—Ibandronate—osteoporosis	6.88e-05	0.000638	CcSEcCtD
Methylprednisolone—Angiopathy—Estradiol—osteoporosis	6.85e-05	0.000635	CcSEcCtD
Methylprednisolone—Shock—Zoledronate—osteoporosis	6.85e-05	0.000635	CcSEcCtD
Methylprednisolone—Paraesthesia—Pamidronate—osteoporosis	6.84e-05	0.000635	CcSEcCtD
Methylprednisolone—Diarrhoea—Alendronate—osteoporosis	6.83e-05	0.000634	CcSEcCtD
Methylprednisolone—Asthenia—Calcitriol—osteoporosis	6.83e-05	0.000634	CcSEcCtD
Methylprednisolone—Nervous system disorder—Zoledronate—osteoporosis	6.83e-05	0.000633	CcSEcCtD
Methylprednisolone—Immune system disorder—Estradiol—osteoporosis	6.82e-05	0.000633	CcSEcCtD
Methylprednisolone—Mediastinal disorder—Estradiol—osteoporosis	6.8e-05	0.000631	CcSEcCtD
Methylprednisolone—Tachycardia—Zoledronate—osteoporosis	6.79e-05	0.00063	CcSEcCtD
Methylprednisolone—NR3C1—Endoderm Differentiation—PTHLH—osteoporosis	6.78e-05	0.0166	CbGpPWpGaD
Methylprednisolone—Feeling abnormal—Ethinyl Estradiol—osteoporosis	6.77e-05	0.000628	CcSEcCtD
Methylprednisolone—Skin disorder—Zoledronate—osteoporosis	6.76e-05	0.000627	CcSEcCtD
Methylprednisolone—NR3C1—Glucocorticoid receptor regulatory network—NFATC1—osteoporosis	6.76e-05	0.0166	CbGpPWpGaD
Methylprednisolone—Pruritus—Calcitriol—osteoporosis	6.74e-05	0.000625	CcSEcCtD
Methylprednisolone—Hyperhidrosis—Zoledronate—osteoporosis	6.73e-05	0.000624	CcSEcCtD
Methylprednisolone—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	6.72e-05	0.000624	CcSEcCtD
Methylprednisolone—Diarrhoea—Raloxifene—osteoporosis	6.72e-05	0.000624	CcSEcCtD
Methylprednisolone—Dyspepsia—Pamidronate—osteoporosis	6.71e-05	0.000622	CcSEcCtD
Methylprednisolone—Dizziness—Estropipate—osteoporosis	6.71e-05	0.000622	CcSEcCtD
Methylprednisolone—Anaphylactic shock—Conjugated Estrogens—osteoporosis	6.7e-05	0.000622	CcSEcCtD
Methylprednisolone—Infection—Conjugated Estrogens—osteoporosis	6.66e-05	0.000618	CcSEcCtD
Methylprednisolone—Diarrhoea—Ibandronate—osteoporosis	6.65e-05	0.000617	CcSEcCtD
Methylprednisolone—ABCB1—Allograft Rejection—TUBA1B—osteoporosis	6.62e-05	0.0162	CbGpPWpGaD
Methylprednisolone—Mental disorder—Estradiol—osteoporosis	6.61e-05	0.000614	CcSEcCtD
Methylprednisolone—Dizziness—Alendronate—osteoporosis	6.61e-05	0.000613	CcSEcCtD
Methylprednisolone—Shock—Conjugated Estrogens—osteoporosis	6.59e-05	0.000612	CcSEcCtD
Methylprednisolone—Nervous system disorder—Conjugated Estrogens—osteoporosis	6.57e-05	0.00061	CcSEcCtD
Methylprednisolone—Erythema—Estradiol—osteoporosis	6.57e-05	0.00061	CcSEcCtD
Methylprednisolone—Malnutrition—Estradiol—osteoporosis	6.57e-05	0.00061	CcSEcCtD
Methylprednisolone—Fatigue—Pamidronate—osteoporosis	6.57e-05	0.000609	CcSEcCtD
Methylprednisolone—Gastrointestinal pain—Risedronate—osteoporosis	6.55e-05	0.000608	CcSEcCtD
Methylprednisolone—Tachycardia—Conjugated Estrogens—osteoporosis	6.54e-05	0.000607	CcSEcCtD
Methylprednisolone—Urticaria—Ethinyl Estradiol—osteoporosis	6.53e-05	0.000606	CcSEcCtD
Methylprednisolone—Diarrhoea—Calcitriol—osteoporosis	6.51e-05	0.000604	CcSEcCtD
Methylprednisolone—Skin disorder—Conjugated Estrogens—osteoporosis	6.51e-05	0.000604	CcSEcCtD
Methylprednisolone—Hypotension—Zoledronate—osteoporosis	6.5e-05	0.000603	CcSEcCtD
Methylprednisolone—Abdominal pain—Ethinyl Estradiol—osteoporosis	6.5e-05	0.000603	CcSEcCtD
Methylprednisolone—Dizziness—Raloxifene—osteoporosis	6.5e-05	0.000603	CcSEcCtD
Methylprednisolone—Hyperhidrosis—Conjugated Estrogens—osteoporosis	6.48e-05	0.000601	CcSEcCtD
Methylprednisolone—Vomiting—Estropipate—osteoporosis	6.45e-05	0.000598	CcSEcCtD
Methylprednisolone—Dizziness—Ibandronate—osteoporosis	6.43e-05	0.000597	CcSEcCtD
Methylprednisolone—Rash—Estropipate—osteoporosis	6.39e-05	0.000593	CcSEcCtD
Methylprednisolone—Dermatitis—Estropipate—osteoporosis	6.39e-05	0.000593	CcSEcCtD
Methylprednisolone—Urticaria—Risedronate—osteoporosis	6.37e-05	0.000591	CcSEcCtD
Methylprednisolone—Headache—Estropipate—osteoporosis	6.35e-05	0.000589	CcSEcCtD
Methylprednisolone—Vomiting—Alendronate—osteoporosis	6.35e-05	0.000589	CcSEcCtD
Methylprednisolone—Musculoskeletal discomfort—Zoledronate—osteoporosis	6.34e-05	0.000588	CcSEcCtD
Methylprednisolone—Abdominal pain—Risedronate—osteoporosis	6.34e-05	0.000588	CcSEcCtD
Methylprednisolone—Rash—Alendronate—osteoporosis	6.3e-05	0.000584	CcSEcCtD
Methylprednisolone—Insomnia—Zoledronate—osteoporosis	6.29e-05	0.000584	CcSEcCtD
Methylprednisolone—Dermatitis—Alendronate—osteoporosis	6.29e-05	0.000584	CcSEcCtD
Methylprednisolone—Feeling abnormal—Pamidronate—osteoporosis	6.28e-05	0.000583	CcSEcCtD
Methylprednisolone—Hypotension—Conjugated Estrogens—osteoporosis	6.26e-05	0.000581	CcSEcCtD
Methylprednisolone—Headache—Alendronate—osteoporosis	6.26e-05	0.000581	CcSEcCtD
Methylprednisolone—Paraesthesia—Zoledronate—osteoporosis	6.25e-05	0.00058	CcSEcCtD
Methylprednisolone—Vomiting—Raloxifene—osteoporosis	6.25e-05	0.00058	CcSEcCtD
Methylprednisolone—Gastrointestinal pain—Pamidronate—osteoporosis	6.23e-05	0.000578	CcSEcCtD
Methylprednisolone—Rash—Raloxifene—osteoporosis	6.19e-05	0.000575	CcSEcCtD
Methylprednisolone—Dermatitis—Raloxifene—osteoporosis	6.19e-05	0.000574	CcSEcCtD
Methylprednisolone—Vomiting—Ibandronate—osteoporosis	6.18e-05	0.000574	CcSEcCtD
Methylprednisolone—NR3C1—Glucocorticoid receptor regulatory network—BGLAP—osteoporosis	6.16e-05	0.0151	CbGpPWpGaD
Methylprednisolone—Headache—Raloxifene—osteoporosis	6.15e-05	0.000571	CcSEcCtD
Methylprednisolone—Rash—Ibandronate—osteoporosis	6.13e-05	0.000569	CcSEcCtD
Methylprednisolone—Dermatitis—Ibandronate—osteoporosis	6.13e-05	0.000568	CcSEcCtD
Methylprednisolone—Dyspepsia—Zoledronate—osteoporosis	6.13e-05	0.000568	CcSEcCtD
Methylprednisolone—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	6.11e-05	0.000566	CcSEcCtD
Methylprednisolone—Ill-defined disorder—Estradiol—osteoporosis	6.1e-05	0.000566	CcSEcCtD
Methylprednisolone—Headache—Ibandronate—osteoporosis	6.09e-05	0.000565	CcSEcCtD
Methylprednisolone—Insomnia—Conjugated Estrogens—osteoporosis	6.06e-05	0.000562	CcSEcCtD
Methylprednisolone—Hypersensitivity—Ethinyl Estradiol—osteoporosis	6.06e-05	0.000562	CcSEcCtD
Methylprednisolone—Vomiting—Calcitriol—osteoporosis	6.05e-05	0.000562	CcSEcCtD
Methylprednisolone—Nausea—Estropipate—osteoporosis	6.02e-05	0.000559	CcSEcCtD
Methylprednisolone—Abdominal pain—Pamidronate—osteoporosis	6.02e-05	0.000559	CcSEcCtD
Methylprednisolone—Paraesthesia—Conjugated Estrogens—osteoporosis	6.02e-05	0.000558	CcSEcCtD
Methylprednisolone—Angioedema—Estradiol—osteoporosis	6e-05	0.000557	CcSEcCtD
Methylprednisolone—Rash—Calcitriol—osteoporosis	6e-05	0.000557	CcSEcCtD
Methylprednisolone—Fatigue—Zoledronate—osteoporosis	6e-05	0.000557	CcSEcCtD
Methylprednisolone—Dermatitis—Calcitriol—osteoporosis	6e-05	0.000556	CcSEcCtD
Methylprednisolone—Headache—Calcitriol—osteoporosis	5.96e-05	0.000553	CcSEcCtD
Methylprednisolone—Nausea—Alendronate—osteoporosis	5.93e-05	0.00055	CcSEcCtD
Methylprednisolone—Malaise—Estradiol—osteoporosis	5.93e-05	0.00055	CcSEcCtD
Methylprednisolone—Hypersensitivity—Risedronate—osteoporosis	5.91e-05	0.000548	CcSEcCtD
Methylprednisolone—Vertigo—Estradiol—osteoporosis	5.9e-05	0.000548	CcSEcCtD
Methylprednisolone—Dyspepsia—Conjugated Estrogens—osteoporosis	5.9e-05	0.000547	CcSEcCtD
Methylprednisolone—Asthenia—Ethinyl Estradiol—osteoporosis	5.9e-05	0.000547	CcSEcCtD
Methylprednisolone—Syncope—Estradiol—osteoporosis	5.89e-05	0.000547	CcSEcCtD
Methylprednisolone—Nausea—Raloxifene—osteoporosis	5.84e-05	0.000541	CcSEcCtD
Methylprednisolone—Pruritus—Ethinyl Estradiol—osteoporosis	5.82e-05	0.00054	CcSEcCtD
Methylprednisolone—Fatigue—Conjugated Estrogens—osteoporosis	5.78e-05	0.000536	CcSEcCtD
Methylprednisolone—Nausea—Ibandronate—osteoporosis	5.78e-05	0.000536	CcSEcCtD
Methylprednisolone—Loss of consciousness—Estradiol—osteoporosis	5.78e-05	0.000536	CcSEcCtD
Methylprednisolone—Asthenia—Risedronate—osteoporosis	5.75e-05	0.000534	CcSEcCtD
Methylprednisolone—Feeling abnormal—Zoledronate—osteoporosis	5.74e-05	0.000532	CcSEcCtD
Methylprednisolone—NR3C1—Nuclear Receptor transcription pathway—VDR—osteoporosis	5.72e-05	0.014	CbGpPWpGaD
Methylprednisolone—Gastrointestinal pain—Zoledronate—osteoporosis	5.69e-05	0.000528	CcSEcCtD
Methylprednisolone—Hypertension—Estradiol—osteoporosis	5.67e-05	0.000526	CcSEcCtD
Methylprednisolone—Pruritus—Risedronate—osteoporosis	5.67e-05	0.000526	CcSEcCtD
Methylprednisolone—Nausea—Calcitriol—osteoporosis	5.65e-05	0.000525	CcSEcCtD
Methylprednisolone—Diarrhoea—Ethinyl Estradiol—osteoporosis	5.62e-05	0.000522	CcSEcCtD
Methylprednisolone—Hypersensitivity—Pamidronate—osteoporosis	5.61e-05	0.000521	CcSEcCtD
Methylprednisolone—Arthralgia—Estradiol—osteoporosis	5.59e-05	0.000519	CcSEcCtD
Methylprednisolone—Myalgia—Estradiol—osteoporosis	5.59e-05	0.000519	CcSEcCtD
Methylprednisolone—Anxiety—Estradiol—osteoporosis	5.58e-05	0.000517	CcSEcCtD
Methylprednisolone—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	5.56e-05	0.000515	CcSEcCtD
Methylprednisolone—NR3C1—Signaling events mediated by HDAC Class II—ESR1—osteoporosis	5.53e-05	0.0136	CbGpPWpGaD
Methylprednisolone—NR3C1—Nuclear Receptors—ESR1—osteoporosis	5.53e-05	0.0136	CbGpPWpGaD
Methylprednisolone—Urticaria—Zoledronate—osteoporosis	5.53e-05	0.000513	CcSEcCtD
Methylprednisolone—Discomfort—Estradiol—osteoporosis	5.53e-05	0.000513	CcSEcCtD
Methylprednisolone—Abdominal pain—Zoledronate—osteoporosis	5.5e-05	0.00051	CcSEcCtD
Methylprednisolone—Diarrhoea—Risedronate—osteoporosis	5.48e-05	0.000509	CcSEcCtD
Methylprednisolone—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	5.48e-05	0.000508	CcSEcCtD
Methylprednisolone—Asthenia—Pamidronate—osteoporosis	5.47e-05	0.000507	CcSEcCtD
Methylprednisolone—Dizziness—Ethinyl Estradiol—osteoporosis	5.44e-05	0.000504	CcSEcCtD
Methylprednisolone—Confusional state—Estradiol—osteoporosis	5.41e-05	0.000502	CcSEcCtD
Methylprednisolone—Pruritus—Pamidronate—osteoporosis	5.39e-05	0.0005	CcSEcCtD
Methylprednisolone—Anaphylactic shock—Estradiol—osteoporosis	5.36e-05	0.000498	CcSEcCtD
Methylprednisolone—Infection—Estradiol—osteoporosis	5.33e-05	0.000494	CcSEcCtD
Methylprednisolone—Urticaria—Conjugated Estrogens—osteoporosis	5.32e-05	0.000494	CcSEcCtD
Methylprednisolone—Dizziness—Risedronate—osteoporosis	5.3e-05	0.000492	CcSEcCtD
Methylprednisolone—Abdominal pain—Conjugated Estrogens—osteoporosis	5.3e-05	0.000491	CcSEcCtD
Methylprednisolone—Shock—Estradiol—osteoporosis	5.28e-05	0.00049	CcSEcCtD
Methylprednisolone—Nervous system disorder—Estradiol—osteoporosis	5.26e-05	0.000488	CcSEcCtD
Methylprednisolone—Tachycardia—Estradiol—osteoporosis	5.23e-05	0.000486	CcSEcCtD
Methylprednisolone—Vomiting—Ethinyl Estradiol—osteoporosis	5.23e-05	0.000485	CcSEcCtD
Methylprednisolone—Diarrhoea—Pamidronate—osteoporosis	5.21e-05	0.000484	CcSEcCtD
Methylprednisolone—Skin disorder—Estradiol—osteoporosis	5.21e-05	0.000483	CcSEcCtD
Methylprednisolone—Hyperhidrosis—Estradiol—osteoporosis	5.18e-05	0.000481	CcSEcCtD
Methylprednisolone—Rash—Ethinyl Estradiol—osteoporosis	5.18e-05	0.000481	CcSEcCtD
Methylprednisolone—Dermatitis—Ethinyl Estradiol—osteoporosis	5.18e-05	0.00048	CcSEcCtD
Methylprednisolone—Headache—Ethinyl Estradiol—osteoporosis	5.15e-05	0.000478	CcSEcCtD
Methylprednisolone—Hypersensitivity—Zoledronate—osteoporosis	5.13e-05	0.000476	CcSEcCtD
Methylprednisolone—Vomiting—Risedronate—osteoporosis	5.1e-05	0.000473	CcSEcCtD
Methylprednisolone—Rash—Risedronate—osteoporosis	5.05e-05	0.000469	CcSEcCtD
Methylprednisolone—Dermatitis—Risedronate—osteoporosis	5.05e-05	0.000468	CcSEcCtD
Methylprednisolone—Dizziness—Pamidronate—osteoporosis	5.04e-05	0.000467	CcSEcCtD
Methylprednisolone—Headache—Risedronate—osteoporosis	5.02e-05	0.000466	CcSEcCtD
Methylprednisolone—Asthenia—Zoledronate—osteoporosis	4.99e-05	0.000463	CcSEcCtD
Methylprednisolone—Hypersensitivity—Conjugated Estrogens—osteoporosis	4.94e-05	0.000458	CcSEcCtD
Methylprednisolone—Pruritus—Zoledronate—osteoporosis	4.92e-05	0.000457	CcSEcCtD
Methylprednisolone—Musculoskeletal discomfort—Estradiol—osteoporosis	4.89e-05	0.000453	CcSEcCtD
Methylprednisolone—Nausea—Ethinyl Estradiol—osteoporosis	4.88e-05	0.000453	CcSEcCtD
Methylprednisolone—Insomnia—Estradiol—osteoporosis	4.85e-05	0.00045	CcSEcCtD
Methylprednisolone—Vomiting—Pamidronate—osteoporosis	4.84e-05	0.000449	CcSEcCtD
Methylprednisolone—Paraesthesia—Estradiol—osteoporosis	4.82e-05	0.000447	CcSEcCtD
Methylprednisolone—Asthenia—Conjugated Estrogens—osteoporosis	4.81e-05	0.000446	CcSEcCtD
Methylprednisolone—Rash—Pamidronate—osteoporosis	4.8e-05	0.000446	CcSEcCtD
Methylprednisolone—Dermatitis—Pamidronate—osteoporosis	4.8e-05	0.000445	CcSEcCtD
Methylprednisolone—Headache—Pamidronate—osteoporosis	4.77e-05	0.000443	CcSEcCtD
Methylprednisolone—Diarrhoea—Zoledronate—osteoporosis	4.76e-05	0.000442	CcSEcCtD
Methylprednisolone—Nausea—Risedronate—osteoporosis	4.76e-05	0.000442	CcSEcCtD
Methylprednisolone—Pruritus—Conjugated Estrogens—osteoporosis	4.74e-05	0.00044	CcSEcCtD
Methylprednisolone—Dyspepsia—Estradiol—osteoporosis	4.72e-05	0.000438	CcSEcCtD
Methylprednisolone—Fatigue—Estradiol—osteoporosis	4.62e-05	0.000429	CcSEcCtD
Methylprednisolone—Dizziness—Zoledronate—osteoporosis	4.6e-05	0.000427	CcSEcCtD
Methylprednisolone—Diarrhoea—Conjugated Estrogens—osteoporosis	4.59e-05	0.000425	CcSEcCtD
Methylprednisolone—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—osteoporosis	4.56e-05	0.0112	CbGpPWpGaD
Methylprednisolone—Nausea—Pamidronate—osteoporosis	4.53e-05	0.00042	CcSEcCtD
Methylprednisolone—NR3C1—Adipogenesis—WNT1—osteoporosis	4.47e-05	0.0109	CbGpPWpGaD
Methylprednisolone—Dizziness—Conjugated Estrogens—osteoporosis	4.43e-05	0.000411	CcSEcCtD
Methylprednisolone—Vomiting—Zoledronate—osteoporosis	4.42e-05	0.000411	CcSEcCtD
Methylprednisolone—Feeling abnormal—Estradiol—osteoporosis	4.42e-05	0.00041	CcSEcCtD
Methylprednisolone—Rash—Zoledronate—osteoporosis	4.39e-05	0.000407	CcSEcCtD
Methylprednisolone—Gastrointestinal pain—Estradiol—osteoporosis	4.39e-05	0.000407	CcSEcCtD
Methylprednisolone—Dermatitis—Zoledronate—osteoporosis	4.38e-05	0.000407	CcSEcCtD
Methylprednisolone—NR3C1—Nuclear Receptor transcription pathway—ESR1—osteoporosis	4.37e-05	0.0107	CbGpPWpGaD
Methylprednisolone—Headache—Zoledronate—osteoporosis	4.36e-05	0.000405	CcSEcCtD
Methylprednisolone—Vomiting—Conjugated Estrogens—osteoporosis	4.26e-05	0.000395	CcSEcCtD
Methylprednisolone—Urticaria—Estradiol—osteoporosis	4.26e-05	0.000395	CcSEcCtD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—GAPDH—osteoporosis	4.25e-05	0.0104	CbGpPWpGaD
Methylprednisolone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	4.25e-05	0.0104	CbGpPWpGaD
Methylprednisolone—Abdominal pain—Estradiol—osteoporosis	4.24e-05	0.000393	CcSEcCtD
Methylprednisolone—Rash—Conjugated Estrogens—osteoporosis	4.23e-05	0.000392	CcSEcCtD
Methylprednisolone—Dermatitis—Conjugated Estrogens—osteoporosis	4.22e-05	0.000392	CcSEcCtD
Methylprednisolone—Headache—Conjugated Estrogens—osteoporosis	4.2e-05	0.000389	CcSEcCtD
Methylprednisolone—NR3C1—Transcription factor regulation in adipogenesis—TNF—osteoporosis	4.15e-05	0.0102	CbGpPWpGaD
Methylprednisolone—Nausea—Zoledronate—osteoporosis	4.13e-05	0.000384	CcSEcCtD
Methylprednisolone—NR3C1—Adipogenesis—BMP2—osteoporosis	4.04e-05	0.0099	CbGpPWpGaD
Methylprednisolone—Nausea—Conjugated Estrogens—osteoporosis	3.98e-05	0.000369	CcSEcCtD
Methylprednisolone—Hypersensitivity—Estradiol—osteoporosis	3.95e-05	0.000367	CcSEcCtD
Methylprednisolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—VDR—osteoporosis	3.95e-05	0.00969	CbGpPWpGaD
Methylprednisolone—Asthenia—Estradiol—osteoporosis	3.85e-05	0.000357	CcSEcCtD
Methylprednisolone—Pruritus—Estradiol—osteoporosis	3.79e-05	0.000352	CcSEcCtD
Methylprednisolone—Diarrhoea—Estradiol—osteoporosis	3.67e-05	0.00034	CcSEcCtD
Methylprednisolone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	3.62e-05	0.00888	CbGpPWpGaD
Methylprednisolone—ABCB1—HIF-1-alpha transcription factor network—ENO1—osteoporosis	3.58e-05	0.00877	CbGpPWpGaD
Methylprednisolone—CYP3A4—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	3.57e-05	0.00876	CbGpPWpGaD
Methylprednisolone—Dizziness—Estradiol—osteoporosis	3.55e-05	0.000329	CcSEcCtD
Methylprednisolone—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—osteoporosis	3.41e-05	0.00836	CbGpPWpGaD
Methylprednisolone—Vomiting—Estradiol—osteoporosis	3.41e-05	0.000316	CcSEcCtD
Methylprednisolone—NR3C1—AP-1 transcription factor network—ESR1—osteoporosis	3.39e-05	0.00832	CbGpPWpGaD
Methylprednisolone—Rash—Estradiol—osteoporosis	3.38e-05	0.000314	CcSEcCtD
Methylprednisolone—Dermatitis—Estradiol—osteoporosis	3.38e-05	0.000313	CcSEcCtD
Methylprednisolone—Headache—Estradiol—osteoporosis	3.36e-05	0.000312	CcSEcCtD
Methylprednisolone—NR3C1—Transcription factor regulation in adipogenesis—IL6—osteoporosis	3.35e-05	0.00821	CbGpPWpGaD
Methylprednisolone—Nausea—Estradiol—osteoporosis	3.19e-05	0.000296	CcSEcCtD
Methylprednisolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—ESR1—osteoporosis	3.02e-05	0.0074	CbGpPWpGaD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—ESR2—osteoporosis	2.95e-05	0.00722	CbGpPWpGaD
Methylprednisolone—CYP3A4—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	2.94e-05	0.0072	CbGpPWpGaD
Methylprednisolone—NR3C1—Glucocorticoid receptor regulatory network—POMC—osteoporosis	2.69e-05	0.00659	CbGpPWpGaD
Methylprednisolone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	2.62e-05	0.00642	CbGpPWpGaD
Methylprednisolone—CYP3A4—Tryptophan metabolism—CYP19A1—osteoporosis	2.35e-05	0.00577	CbGpPWpGaD
Methylprednisolone—NR3C1—Adipogenesis—IRS2—osteoporosis	2.21e-05	0.00543	CbGpPWpGaD
Methylprednisolone—NR3C1—Adipogenesis—LEP—osteoporosis	2.17e-05	0.00531	CbGpPWpGaD
Methylprednisolone—ABCB1—HIF-1-alpha transcription factor network—LEP—osteoporosis	2e-05	0.00491	CbGpPWpGaD
Methylprednisolone—NR3C1—Adipogenesis—IRS1—osteoporosis	1.93e-05	0.00474	CbGpPWpGaD
Methylprednisolone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	1.9e-05	0.00466	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—RAP1A—osteoporosis	1.89e-05	0.00464	CbGpPWpGaD
Methylprednisolone—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	1.88e-05	0.0046	CbGpPWpGaD
Methylprednisolone—NR3C1—Endoderm Differentiation—TGFB1—osteoporosis	1.8e-05	0.00442	CbGpPWpGaD
Methylprednisolone—NR3C1—Adipogenesis—IGF1—osteoporosis	1.79e-05	0.00439	CbGpPWpGaD
Methylprednisolone—NR3C1—AP-1 transcription factor network—MYC—osteoporosis	1.77e-05	0.00433	CbGpPWpGaD
Methylprednisolone—NR3C1—AP-1 transcription factor network—TGFB1—osteoporosis	1.76e-05	0.00432	CbGpPWpGaD
Methylprednisolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—osteoporosis	1.57e-05	0.00385	CbGpPWpGaD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—IL6R—osteoporosis	1.57e-05	0.00385	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—U2AF1—osteoporosis	1.56e-05	0.00383	CbGpPWpGaD
Methylprednisolone—CYP3A4—Biological oxidations—CYP27A1—osteoporosis	1.56e-05	0.00382	CbGpPWpGaD
Methylprednisolone—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	1.54e-05	0.00378	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metapathway biotransformation—CYP27A1—osteoporosis	1.54e-05	0.00377	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—osteoporosis	1.35e-05	0.0033	CbGpPWpGaD
Methylprednisolone—NR3C1—AP-1 transcription factor network—IL6—osteoporosis	1.33e-05	0.00325	CbGpPWpGaD
Methylprednisolone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—osteoporosis	1.26e-05	0.00309	CbGpPWpGaD
Methylprednisolone—NR3C1—Generic Transcription Pathway—ESR2—osteoporosis	1.25e-05	0.00305	CbGpPWpGaD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—IL1B—osteoporosis	1.19e-05	0.00293	CbGpPWpGaD
Methylprednisolone—NR3C1—Glucocorticoid receptor regulatory network—IL6—osteoporosis	1.17e-05	0.00287	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—RPL24—osteoporosis	1.16e-05	0.00285	CbGpPWpGaD
Methylprednisolone—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	1.14e-05	0.0028	CbGpPWpGaD
Methylprednisolone—ABCB1—Allograft Rejection—IL1B—osteoporosis	1.1e-05	0.00271	CbGpPWpGaD
Methylprednisolone—NR3C1—Adipogenesis—TGFB1—osteoporosis	1.07e-05	0.00263	CbGpPWpGaD
Methylprednisolone—ABCB1—Transmembrane transport of small molecules—ANXA2—osteoporosis	1.06e-05	0.00259	CbGpPWpGaD
Methylprednisolone—NR3C1—Adipogenesis—TNF—osteoporosis	1e-05	0.00246	CbGpPWpGaD
Methylprednisolone—NR3C1—Generic Transcription Pathway—VDR—osteoporosis	9.88e-06	0.00242	CbGpPWpGaD
Methylprednisolone—CYP3A4—Phase 1 - Functionalization of compounds—POMC—osteoporosis	9.27e-06	0.00227	CbGpPWpGaD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—TNF—osteoporosis	8.66e-06	0.00212	CbGpPWpGaD
Methylprednisolone—ABCB1—Allograft Rejection—TGFB1—osteoporosis	8.59e-06	0.0021	CbGpPWpGaD
Methylprednisolone—CYP3A4—Biological oxidations—CYP19A1—osteoporosis	8.19e-06	0.00201	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	8.17e-06	0.002	CbGpPWpGaD
Methylprednisolone—NR3C1—Adipogenesis—IL6—osteoporosis	8.09e-06	0.00198	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metapathway biotransformation—CYP19A1—osteoporosis	8.08e-06	0.00198	CbGpPWpGaD
Methylprednisolone—ABCB1—Allograft Rejection—TNF—osteoporosis	8.02e-06	0.00197	CbGpPWpGaD
Methylprednisolone—NR3C1—Generic Transcription Pathway—ESR1—osteoporosis	7.55e-06	0.00185	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—FDPS—osteoporosis	7.54e-06	0.00185	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—PKM—osteoporosis	7.54e-06	0.00185	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—GPD2—osteoporosis	7.14e-06	0.00175	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—PGLS—osteoporosis	7.14e-06	0.00175	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	7.07e-06	0.00173	CbGpPWpGaD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—IL6—osteoporosis	6.99e-06	0.00171	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—PSMA2—osteoporosis	6.71e-06	0.00164	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—PSMA5—osteoporosis	6.71e-06	0.00164	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—ATIC—osteoporosis	6.53e-06	0.0016	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—PNP—osteoporosis	6.53e-06	0.0016	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—ESR2—osteoporosis	5.99e-06	0.00147	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—CA2—osteoporosis	5.56e-06	0.00136	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—OXCT1—osteoporosis	5.56e-06	0.00136	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—MGLL—osteoporosis	5.41e-06	0.00133	CbGpPWpGaD
Methylprednisolone—CYP3A4—Biological oxidations—POMC—osteoporosis	4.92e-06	0.00121	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—VDR—osteoporosis	4.76e-06	0.00117	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—PKM—osteoporosis	4.64e-06	0.00114	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—FDPS—osteoporosis	4.64e-06	0.00114	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—IDH2—osteoporosis	4.6e-06	0.00113	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—PGLS—osteoporosis	4.4e-06	0.00108	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—GPD2—osteoporosis	4.4e-06	0.00108	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—CYP27A1—osteoporosis	4.33e-06	0.00106	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	4.25e-06	0.00104	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	4.24e-06	0.00104	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—ACP5—osteoporosis	4.21e-06	0.00103	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—PNP—osteoporosis	4.03e-06	0.000987	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—ATIC—osteoporosis	4.03e-06	0.000987	CbGpPWpGaD
Methylprednisolone—ABCB1—Transmembrane transport of small molecules—ADCY5—osteoporosis	3.97e-06	0.000972	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	3.96e-06	0.00097	CbGpPWpGaD
Methylprednisolone—NR3C1—Generic Transcription Pathway—MYC—osteoporosis	3.93e-06	0.000963	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—TPI1—osteoporosis	3.91e-06	0.00096	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—P4HB—osteoporosis	3.68e-06	0.000902	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—ESR1—osteoporosis	3.64e-06	0.000891	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—GAPDH—osteoporosis	3.61e-06	0.000886	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—RAP1A—osteoporosis	3.52e-06	0.000862	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—CA2—osteoporosis	3.42e-06	0.000839	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—OXCT1—osteoporosis	3.42e-06	0.000839	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—MGLL—osteoporosis	3.34e-06	0.000818	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—ENO1—osteoporosis	2.84e-06	0.000697	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—IDH2—osteoporosis	2.84e-06	0.000695	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—PSMA2—osteoporosis	2.8e-06	0.000687	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—PSMA5—osteoporosis	2.8e-06	0.000687	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—CYP27A1—osteoporosis	2.67e-06	0.000654	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—ACP5—osteoporosis	2.59e-06	0.000636	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—TPI1—osteoporosis	2.41e-06	0.000591	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—CYP19A1—osteoporosis	2.27e-06	0.000557	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—P4HB—osteoporosis	2.27e-06	0.000556	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—GAPDH—osteoporosis	2.23e-06	0.000546	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—RAP1A—osteoporosis	2.17e-06	0.000531	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—MYC—osteoporosis	1.89e-06	0.000464	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—ADCY5—osteoporosis	1.86e-06	0.000455	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—GPX1—osteoporosis	1.85e-06	0.000454	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—ENO1—osteoporosis	1.75e-06	0.00043	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—PSMA2—osteoporosis	1.73e-06	0.000423	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—PSMA5—osteoporosis	1.73e-06	0.000423	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—MTHFR—osteoporosis	1.71e-06	0.000419	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—CYP19A1—osteoporosis	1.4e-06	0.000343	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—POMC—osteoporosis	1.37e-06	0.000335	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—ADCY5—osteoporosis	1.14e-06	0.000281	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—GPX1—osteoporosis	1.14e-06	0.00028	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—MTHFR—osteoporosis	1.05e-06	0.000258	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—POMC—osteoporosis	8.42e-07	0.000206	CbGpPWpGaD
